

IAP20 Dec 22 2005
ORAL MULTI-FUNCTIONAL PHARMACEUTICAL
CAPSULE PREPARATIONS OF PROTON PUMP INHIBITORS

Field of the Invention

The present invention relates to oral pharmaceutical preparations and methods of making such preparations. More specifically, the invention is a multi-functional pharmaceutical capsule (MFC) that comprises multiple populations of pharmaceutical actives together with multiple populations of a basic substance either of which is provided as beads, pellets, tablets and/or granules. Each population is functionally distinct. The capsule provides multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma.

Background of the Invention

Throughout this application, various references are cited to describe more fully the state of the art to which this invention pertains. The disclosure of these references are hereby incorporated by reference into the present disclosure.

Acid labile H^+K^+ -ATPase inhibitors, known as gastric proton pump inhibitors (PPI), are known and include the generic compounds such as omeprazole, lansoprazole, pantoprazole, pariprazole, rabiprazole and leminoprazole as disclosed for example in U.S. Pat. Nos. 4,045,563; 4,255,431; 4,628,098; 4,686,230; 4,758,579; 4,965,269; 5,021,433; 5,430,042 5,045,552 and 5,708,017. In general, the proton pump inhibitors of gastric acid secretion work by undergoing a rearrangement to form a thiophilic species which then covalently binds to gastric H^+K^+ ATPase, the enzyme involved in the final step of proton production in the parietal cells, and thereby inhibits the enzyme.

Proton pump inhibitor compounds are useful for inhibiting gastric acid secretion in mammals and man and are used for prevention and treatment of gastric acid related diseases such as reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for

treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients
5 in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre-and postoperatively to prevent acid aspiration of gastric add and to prevent and treat stress ulceration. Further, they may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these.

10 Proton pump inhibitor compounds are susceptible to degradation or transformation in acidic media. The degradation is catalyzed by acidic compounds and is more stabilized in mixtures with alkaline compounds. The stability of proton pump inhibitor compounds may also be affected by moisture, heat, organic solvents and to some degree by light. For example,
15 proton pump inhibitor compounds such as pyridyl methyl sulfinyl benzimidazoles (having a pK_a of 4.0 to 5.0) have a mechanism of action requiring accumulation in the acidic space of the parietal cell (secretory canaliculus, pH ca. 1.0) followed by subsequent hydrogen ion catalyzed conversion to the reactive thiophilic species that is capable of inhibiting the
20 gastric ATPase enzyme resulting in effective inhibition of gastric secretion. Due to this mechanism this compound requires specialized gastro protection to remain active for duodenal absorption. For this reason, and due to sensitivity to degradation in the acid milieu of the stomach, oral formulations of proton pump inhibitor compounds are usually enteric coated. The need for
25 enteric coating is a shortcoming because enteric coatings are expensive to provide and pH sensitive. Furthermore, the use of enteric coating means that the compound is not being released for absorption in the stomach. Enteric coating layers are known and disclosed for example in U.S. Pat. Nos. 4,853,230, 6,479,075 and 6,296,876.

30 U.S. Pat. No. 5,753,265 discloses an enteric coating layered multiple unit tablet that disperses into a multitude of small units in the stomach upon administration. Many different types of multiple unit dosage forms are known

in the prior art. Usually this type of formulation is requested for controlled release formulations, such as sustained release formulations. Typically, the multiple unit formulation may be a tablet which disintegrates in the stomach to make available a multitude of coated units, or pellets filled in a capsule as is disclosed in EP 0 080 341 and U.S. Pat. No. 4,853,230. However, these do not allow for delivery of the proton pump inhibitor compound throughout the gastrointestinal tract (GIT).

U.S. Pat. No. 4,927,640 discloses a controlled release dosage form that releases the active substance by diffusion through a membrane. The dosage form is a multiple-unit system containing small inert cores coated with active substance and a release controlling polymeric membrane. Other examples of controlled release dosage forms are, for example, described in Aulton M. E. (Churchill Livingstone Ed.), *Pharmaceutics: The science of dosage form design* (1988), p. 316-321. These dosage forms do not sufficiently address the stability issues of the proton pump inhibitor compounds during transit in the gastrointestinal tract.

In practice, problems also arise when enteric coating layered pellets containing acid labile substances, such as proton pump inhibitor compounds, are compressed into tablets. If the enteric coating layer does not withstand the compression of the pellets into a tablet, the susceptible active substance will be destroyed by penetrating acidic gastric juice, i.e. the acid resistance of the enteric coating layer of the pellets will not be sufficient in the tablet after compression. Further, controlled release tablets from enteric coated particles are described in the article: *Drugs Made In Germany*, 37 No. 2 (1994), p. 53. This reference teaches a combination of methacrylic acid copolymer (L30D-55) and a copolymer of ethyl acrylate and methyl methacrylate (NE30D) suitable as a coating polymer for enteric coated particles compressed into tablets. However, the acid resistance of the pellets compressed into tablets is low.

U.S. Pat. No. 6,183,776 discloses an oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor together with an antacid agent or an alginate in a fixed formulation, wherein the proton pump inhibitor

is protected by an enteric coating layer and an optional separating layer is present between the proton pump inhibitor and the enteric coating. The fixed formulation is in the form of a multi-layered tablet, sachets or multiple unit tableted dosage form.

5 The prior art also describes fixed formulations in the form of multiple unit tablets with alkalinizing agents. These multiple unit dosage forms are not the most preferred because the enteric coated proton pump inhibitor is dumped only in the stomach due to the presence of the alkalinizing agent, where the drug is rapidly absorbed and has a short half life.

10 Acid secretion is necessary for the efficacy of proton pump inhibitor compounds because of the requirement for accumulation in the acid space of the parietal cell. Typical plasma half life of proton pump inhibitor compounds and formulations is only between 60 to 90 minutes. As not all acid pumps are active at any one time, rather only about 75% are active on the average
15 during the time the drug is present in the blood following oral administration, in a currently used once-a-day oral administration therapy the maximum inhibition of stimulated acid output is approximately 66%. This is due to a combination of the short plasma half-life of the proton pump inhibitor compound, to the limited number of acid pumps active during presentation of
20 the compound, and to the turn over of acid pumps. Furthermore, in current therapies it is not possible to control night-time acid secretion by an evening therapy of oral administration because the compound is dissipated from the plasma by the time acid secretion is established after midnight.

25 The ideal target for healing in acid related diseases and for treatment of *H. pylori* infection (in conjunction with antibiotics), as well as for relief of symptoms of non-ulcer dyspepsia, would be full inhibition of acid secretion. With the currently used proton pump inhibitor formulations, this is achieved only by intravenous infusion. In the case of the drug omeprazole, intravenous infusion of 8 mg per hour is required.

30 Clearly, there is a need in the art for a formulation of a proton type inhibitor compound, which can attain or approach full inhibition of acid secretion through oral therapy. There is a demand for the development of a

novel proton pump inhibitor formulation that provides good chemical stability and more precise control of the release of the proton pump inhibitor compound within the gastrointestinal environment.

5 Summary of the Invention

According to an aspect of the present invention, there is provided an oral pharmaceutical composition comprising multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising:

- 10 (i) a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate;
- (ii) a population of a basic substance; and
- (iii) a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate.

15 According to another aspect of the present invention, there is provided an oral pharmaceutical composition comprising multiple populations at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising:

- (i) a population of a pharmaceutical active;
- 20 (ii) a population of a basic substance;
- (iii) a population of enteric coated pharmaceutical active; and
- (iv) a population of enteric coated basic substance.

In certain aspects of the invention, the population of either (i) to (iv) is formed about a core material, for example, a sugar sphere or microcrystalline cellulose of about 0.1mm to about 4mm. Alternatively, the population of either
25 (i) to (iv) is provided as a tablet of about 0.5mm to about 20mm. All populations are then provided within a suitable capsule material for oral administration by various mechanisms as further described herein.

In further aspects of the invention, the population of either (i) to (iv) may
30 be about 0.1mm to about 25mm and any desired size therebetween.

According to another aspect of the present invention, there is provided an oral pharmaceutical composition comprising multiple populations of at least

one of beads, pellets, tablets and granules provided in a capsule, the composition comprising:

- (i) a population of a proton pump inhibitor compound;
 - (ii) a population of a basic substance;
 - 5 (iii) a population of enteric coated proton pump inhibitor compound;
- and
- (iv) a population of enteric coated basic substance,
- wherein a separating layer is provided in one or both of (iii) or (iv) to separate the proton pump inhibitor compound or the basic substance from
- 10 the enteric coating.

In aspects, one or more of the populations of (i) to (iv) may further be provided with one or more over-coating layers.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood,

15 however, that the detailed description and the specific examples while indicating embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from the detailed description.

20

Detailed Description of the Invention

The present invention is a multi-functional pharmaceutical capsule for oral use that comprises multiple populations in the form of pellets, tablets, beads and/or granules of a pharmaceutical active substance and multiple

25 populations in the form of pellets, tablets, beads and/or granules of a basic substance, either of which may be optionally coated with a separating layer. A portion of the pharmaceutical active substance and basic substance populations may also be further enteric coated. All of the populations are then provided within a capsule for oral administration to a subject in need of such

30 treatment.

The capsule is suitable for direct oral administration or alternatively may be provided dispersed within a suitable liquid for administration to a

subject with swallowing disorders or formulated for pediatric administration. For example, the capsule may be dispersed within apple sauce or alternatively, in a suitable liquid for feeding through a naso-gastric tube.

5 In embodiments of the invention, a pharmaceutical multi-functional oral dosage capsule comprising multiple populations of pharmaceutical actives are designed to release the pharmaceutical active substance in a rapid, delayed, and/or sustained manner in the gastrointestinal tract (GIT). For instance, the active substance can be delivered to the stomach, between the duodenum and just past the ileocecal junction, and/or further to the ascending,
10 transverse and descending colon. This is also effected through the use of the enteric coated and/or non-enteric coated basic substance. The populations of pharmaceutical actives may be optionally enteric coated. The term "sustained" release is understood to encompass controlled release, extended release, slow release and/or the like.

15 The capsule of the invention can provide for the control of night time acid secretion in a subject with an evening therapy of oral administration. Multiple peaks of the pharmaceutical active substance (e.g. proton pump inhibitor) plasma concentrations may be obtained between one to three, four, six, eight, twelve, sixteen or twenty four hours.

20 In one embodiment, the multi-functional pharmaceutical capsule comprises a population of the pharmaceutical active, which is designed to release the active substance at a first rate, for instance in a rapid manner, such that the active substance can be delivered to the stomach. A further population of the pharmaceutical active, which is designed to release the
25 active substance at a second rate, for instance in a delayed or sustained manner, such that the active substance can be delivered between the duodenum and just past the ileocecal junction and/or further to the ascending, transverse and descending colon. This is also effected through the use of the enteric coated and/or non-enteric coated basic substance.

30 In another embodiment, the multi-functional pharmaceutical capsule comprises a non-enteric coated population of the pharmaceutical active, wherein the pharmaceutical active is delivered to the stomach. A further

enteric coated population of pharmaceutical active is delivered between the duodenum and just past the ileocecal junction and a further enteric coated population of the pharmaceutical active is delivered to the ascending, transverse and descending colon. This is also effected through the use of the enteric coated and/or non-enteric coated basic substance.

As such, the pharmaceutical active substance (e.g. proton pump inhibitor) according to the invention is delivered to multiple sites in the gastrointestinal tract beginning with the stomach despite it's acidic environment.

In a more specific embodiment of the invention, the multi-functional pharmaceutical capsule comprises:

- a first population of pharmaceutical active provided as beads, pellets, tablets or granules and combinations thereof, wherein the pharmaceutical active comprises a pharmaceutical active substance that is rapidly releasable;
- a second population of pharmaceutical active provided as beads, pellets, tablets or granules and combinations thereof, wherein the pharmaceutical active comprises an excipient and a pharmaceutical active substance that is released slower than that of the first population; and
- a population of basic substance provided as beads, pellets, tablets or granules and combinations thereof.

The pharmaceutical capsule of the invention is made such that each population of beads, pellets, tablets or granules has a distinct physiological function.

The function of the first population, comprising the pharmaceutically active substance, such as a proton pump inhibitor compound (PPI), that is rapidly releasable, is to deliver the pharmaceutical active beginning in the stomach. This is made possible due to the presence of an optional excipient and by the stable environment created by the elevated pH environment of the stomach brought about by the rapid disintegration and dissolution of the population of basic substance whose function is to rapidly deliver basic material to the stomach, which allows for precise control of the stomach pH to more than

about 4.0 and less than about 7.0 and, typically, less than about pH 6.3. This pH can also be achieved in less than about 1 hour.

5 The function of the second population, comprising the pharmaceutical active substance, such as a proton pump inhibitor compound (PPI), that is released slower than that of the first population, is to deliver another quantity of the pharmaceutical active between the duodenum and just past the ileocecal junction. This is possible due to the presence of an excipient that controls the release of the pharmaceutical active and the choice and quantity of the basic substance delivered in the stomach by the population of basic
10 substance. The pharmaceutical active substance of the second population may be released in a delayed and/or sustained manner.

The population of either or both the pharmaceutical active substance and the basic substance can be formulated with suitable excipients as is understood by one of skill in the art, keeping in mind the desired rates of
15 releasability of the pharmaceutical active. For example, the excipient, if any, chosen for the first population of the pharmaceutical active will allow for the rapid releasability of the pharmaceutical active. The excipient chosen for the second population of the pharmaceutical active will allow for a comparably less rapid releasability of the pharmaceutical active. Specifically, the excipient
20 for the first population of the pharmaceutical active may be a disintegrating agent and the excipient for the second population of the pharmaceutical active may be a sustained release agent.

In further embodiments, the population(s) of pharmaceutical active(s) have enteric coating(s). The population(s) of pharmaceutical active(s) that
25 have enteric coating(s) can be optionally formulated to have a separating layer prior to the provision of an enteric coating. The separating layer separates the pharmaceutical active from the enteric coating to prevent any reaction occurring between the pharmaceutical active and the enteric coating. Use of the enteric coating can provide the release of the pharmaceutical
30 active in a delayed manner.

In certain aspects of the invention, the pharmaceutically active substance is an acid labile drug and typically, the pharmaceutically active substance is a proton pump inhibitor compound.

5 The pharmaceutical capsule of the invention may further comprise another population of a basic substance, wherein the basic substance is released less rapidly compared to the original basic substance. The use of an excipient and/or the use of an enteric coating may control the release of the basic substance. A separating layer may also be provided, for similar reasons given above, prior to the addition of the enteric coating.

10 Additional populations of pharmaceutical actives may be added to expand on the variability of release of the pharmaceutical active substance. For example, multiple populations of the pharmaceutical active with varying release rates can establish a pulsed release capsule. For instance, a rapid release population, a delayed release population and a sustained release
15 population of pharmaceutical actives together with multiple populations of a basic substance provide one type of pulsed release capsule.

In another specific embodiment of the invention, the multi-functional pharmaceutical capsule comprises:

- 20 - a population of pharmaceutical active substance provided as beads, pellets, tablets or granules and combinations thereof;
- a population of pharmaceutical active substance provided as beads, pellets, tablets or granules and combinations thereof having an enteric coating thereon;
- a population of basic substance provided as beads, pellets, tablets or
25 granules and combinations thereof; and
- a population of basic substance provided as beads, pellets, tablets or granules and combinations thereof having an enteric coating thereon.

An optional separating layer is provided to the populations of pharmaceutical active and basic substance having an enteric coating thereon,
30 the separating layer being provided between the pharmaceutical active or basic substance and the enteric coating layer(s).

The population of either or both the pharmaceutical active substance and the basic substance can be formulated with suitable excipients as is understood by one of skill in the art. Furthermore, the population of pharmaceutical active substance can be optionally formulated to have a
5 separating layer prior to the provision of an enteric coating. Such a separating layer may also be incorporated into a population of the basic substance. In certain aspects of the invention, the pharmaceutically active substance is an acid labile drug and, typically, the pharmaceutically active substance is a proton pump inhibitor compound.

10 The function of the population containing pharmaceutically active substance being a proton pump inhibitor compound (PPI) is to deliver the pharmaceutical active beginning in the stomach. This is made possible by the stable environment created by the elevated pH environment of the stomach brought about by the rapid disintegration and dissolution of the population of
15 basic material whose function is to rapidly deliver basic material to the stomach.

The function of the population containing pharmaceutical active substance being a proton pump inhibitor compound (PPI) having an enteric coating thereon is to deliver another quantity of the pharmaceutical active between
20 the duodenum and just past the ileocecal junction. This is possible due to the presence of the enteric coat and the choice and quantity of the basic material delivered in the stomach by the population of basic material, which allows for precise control of the stomach pH to more than about 4.0 and less than about 7.0 or, typically, less than about pH 6.3. This pH can also be achieved in less
25 than about 1 hour.

The function of the population containing basic material having an enteric coating thereon is to deliver a second quantity of basic material to just past the ileocecal junction to help maintain the pH of the colon to a value not less than about pH 5.0, as a result of which any residual active substance will
30 not be degraded by acid environment that may be encountered in the colon. It is not uncommon for the pH of some sections of the colon to fall to an acidic level.

The invention is suitable for acid labile drugs in general. In embodiments, the acid labile drug is a proton pump inhibitor, a prodrug of a proton pump inhibitor, enantiomers thereof and/or combinations thereof. Suitable proton pump inhibitor pharmaceutical actives for use in the present invention are compounds of gastric proton pump inhibitors or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof. The compounds may be used in neutral form or in the form of an alkaline salt, such as for instance the Mg^{2+} , Ca^{2+} , Na^{+} or K^{+} salts, and more typically Mg^{2+} salts.

Examples of acid-labile proton pump inhibitors (H^{+}/K^{+} ATPase inhibitors) for use in the present invention are substituted pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, such as are disclosed, for example, in EP-A-0 005 129, EP-A-0 166 287, EP-A-0 174 726, EP-A-0 184 322, EP-A-0 261 478 and EP-A-0 268 956. In typical embodiments, the inhibitors are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (INN: rabeprazole).

Still other suitable acid-labile proton pump inhibitors are for example substituted phenylmethylsulfinyl-1H-benzimidazoles, cycloheptapyridin-9-ylsulfinyl-1H-benzimidazoles or pyridin-2-ylmethylsulfinylthienimidazoles as disclosed in DE-A-35 31 487, EP-A-0 434 999 or EP-A-0 234 485. In embodiments are 2-[2-(N-isobutyl-N-methylamino)benzylsulfinyl]benzimidazole (INN: leminoprazole) and 2-(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylsulfinyl)-1H-benzimidazole (INN: nepaprazole).

Acid-labile proton pump inhibitors are chiral compounds. As such, an "acid-labile proton pump inhibitor" also includes the pure enantiomers of the acid-labile proton pump inhibitors and their mixtures in any mixing ratio including the racemates. Enantiomerically pure acid-labile proton pump

inhibitors are disclosed, for example, in WO92/08716 and may include for example Esomeprazole.

5 The acid-labile proton pump inhibitors are present here as such or are typically in the form of their salts with bases. Examples of salts with bases which may be mentioned are sodium, potassium, magnesium or calcium salts. If desired, the salts of the acid-labile proton pump inhibitors with bases can also be present in hydrate form. Such a hydrate of the salt of an acid-labile proton pump inhibitor with a base is disclosed, for example, in WO 91/19710.

10 The pharmaceutical active substance for use in one or more populations of the capsule of the invention may include up to about 80% by weight of the pharmaceutical active in the bead, pellet, tablet or granule. It is understood by one of skill in the art that for human oral delivery, a high drug content is desirable in order that the capsule not be too large for comfortable human oral administration. For veterinary applications, less active can be
15 incorporated per bead, pellet, tablet or granule as the size of the final capsule can be much larger as compared for human oral administration. In embodiments, the amount of proton pump inhibitor active may comprise about 0.1mg to about 5000 mg in the capsule.

20 It is understood by one of skill in the art that one or a combination of proton pump inhibitor compounds as described herein may be used within a single capsule formulation. It is also understood by one of skill in the art, that in addition to the proton pump inhibitor compounds, additional drugs such as, but not limited to, non-steroidal anti-inflammatory agents, prokinetic agents, anticancer agents, anti-emetic agents and combinations thereof may be
25 incorporated into the present capsule formulation and be presented as a population of beads, pellets, tablets and/or granules that may be further enteric coated and may be further provided with a separating layer as described herein. As such, the present invention is suitable for the treatment of a variety of disorders including but not limited to inappropriate gastric acid
30 secretion, reflux esophagitis, gastritis, duodenitis, gastric ulcer, duodenal ulcer, non-ulcer dyspepsia, symptomatic gastro-esophageal reflux disease, gastrinoma, acute upper gastrointestinal bleeding, stress ulceration, psoriasis,

helicobacter disorders and gastrointestinal disorders caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs).

Suitable substances for use as the basic material of the invention may be selected from, but not restricted to, substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; aluminium hydroxide/sodium bicarbonate co-precipitate; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as Al_2O_3 , $6\text{MgOCO}_2 \cdot 12\text{H}_2\text{O}$, $\text{Mg}_6\text{Al}_2(\text{OH})_{16} \cdot \text{CO}_3 \cdot 4\text{H}_2\text{O}$, $\text{MgOAl}_2\text{O}_3 \cdot 2(\text{SiO}_2)_n \cdot \text{H}_2\text{O}$ or similar compounds, organic pH-buffering substances such as trihydroxymethylaminomethane, basic amino acids and their salts or other similar, pharmaceutically acceptable pH-buffering substances. The choice and quantity of the basic material is optimized for effective pH control. It is also understood by one of skill in the art that a combination of one or more different basic materials may be used in a population of basic material.

The basic substance for use in one or more populations of the capsule of the invention may include up to about 80% by weight of basic substance of the bead, pellet, tablet or granule. In formulations of the capsule of the invention the amount of basic substance may be about 0.1mg to about 5000mg. In aspects of the invention the basic substance is capable of raising the pH of a 290ml of HCl solution of pH 2.2 to between pH 4.0 to pH 7.5 in about 15 minutes and not less than about pH 5.5 or more than pH 7.5 for about 48 hours.

To the pharmaceutical active substance or basic material may be added suitable excipients as is understood by one of skill in the art. Excipients are used to obtain preferred handling and processing properties and suitable concentrations of the pharmaceutical active substance. Suitable excipients may be selected from binders, surfactants, fillers, lubricants, disintegrating agents, sustained release agents or other pharmaceutically acceptable ingredients, and combinations thereof. Binders may be selected from, for example, a variety of cellulose derivatives such as hydroxypropyl

5 methylcellulose, hydroxypropyl cellulose and carboxymethyl-cellulose sodium, polyvinyl pyrrolidone, sugars, starches, carrageenan and other pharmaceutically acceptable substances with cohesive properties. Suitable surfactants are found in the groups of pharmaceutically acceptable non-ionic or ionic surfactants such as for instance sodium lauryl sulfate. Some examples of sustained release agents, which may in some cases function as a binder, are pectin, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carragenan, xanthan gum, carbomer, and the like and mixtures thereof.

10 Some examples of disintegrating agents are CrospovidoneTM (ie. homopolymer cross-linked N-vinyl-2-pyrrolidone), sodium starch glycolate, CroscarmelloseTM (ie. cross-linked sodium carboxymethylcellulose), and the like and mixtures thereof.

The amount of excipient per bead, pellet, tablet or granule may

15 comprise about 0.5% to about 95% wgt/wgt of a population in which it is used.

One or more optional separating layers comprising pharmaceutical excipients can be provided to a population of pharmaceutical active substance or basic substance prior to the provision of an enteric coating. The separating layer separates the pharmaceutical active from the outer enteric coating layer.

20 The separating layer(s) can be applied by coating or layering procedures in suitable equipment such as coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating process. As an alternative the separating layer(s) can be applied to the pharmaceutical active or basic substance (provided on a core material discussed further herein) by using powder coating technique. The materials for separating layers are pharmaceutically acceptable compounds such as, for instance, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carragenan, microcrystalline cellulose,

25 carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and

30

anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the separating layer(s).

When the optional separating layer(s) is applied to the core material it may constitute a variable thickness. The maximum thickness of the optional separating layer(s) is normally only limited by processing conditions. Generally, about 0.25% to about 50% by weight of the total bead, pellet, tablet or granule may be provided.

One or more enteric coating layers may be applied to a population of pharmaceutical active substance or to a population of basic material either of which may be optionally covered with separating layer(s) as described herein using a suitable coating technique as is understood by one of skill in the art. The enteric coating material may be dispersed or dissolved in either water or in suitable organic solvents. As enteric coating polymers one or more, separately or in combination, of the following can be used; e.g. solutions or dispersions of methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylethylcellulose, shellac, zein or other suitable enteric coating polymer(s).

The enteric coating layers contain pharmaceutically acceptable plasticizers to obtain the desired mechanical properties, such as flexibility and hardness of the enteric coating layers. Such plasticizers are for instance, but not restricted to, triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, cetyl alcohol, polyethylene glycols, polysorbates or other plasticizers. The amount of plasticizer is optimized for each enteric coating layer formula, in relation to selected enteric coating layer polymer(s), selected plasticizer(s) and the applied amount of said polymer(s), in such a way that the release properties are adjusted so that the acid resistance of the pellets covered with enteric coating layer(s) is optimal. The amount of plasticizer is usually above about 10% by weight of the enteric coating layer polymer(s), about 15-50%, or about 20-50%. Additives such as dispersants, colorants, pigments, polymers e.g. poly(ethylacrylat, methylmethacrylat), anti-tacking

and anti-foaming agents may also be included into the enteric coating layer(s). Other compounds may be added to increase film thickness and to decrease diffusion of acidic gastric juices into the enteric coated populations.

- To protect the second population of active substance or basic material and to obtain an acceptable acid resistance the enteric coating layer(s) constitutes a polymer weight gain of approximately 0.5% to 85% wgt/wgt of the population, or approximately 2% to 15% weight gain. The maximum weight of the polymer in the applied enteric coating layer(s) is normally only limited by processing conditions.
- Populations of pharmaceutical active or populations of basic substance each of which has an enteric coating layer(s) and optional separating layers may further be covered with one or more over-coating layer(s). The over-coating layer(s) can be applied by coating or layering procedures using suitable equipments such as a coating pan, coating granulator or in a fluidized bed apparatus using water and/or organic solvents for the coating or layering process. The materials for over-coating layers are chosen among pharmaceutically acceptable compounds such as, for instance sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, carragenan, microcrystalline cellulose, hydroxypropyl methyl cellulose, carboxymethylcellulose sodium and others, used alone or in mixtures. Additives such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the over-coating layer(s). Said over-coating layer may further prevent potential agglomeration of enteric coating layered pellets or tablets. The maximum thickness of the applied over-coating layer(s) is normally only limited by processing conditions. In general, the amount of over-coating layer is about 0.25% to about 90% weight gain as a percent of weight of a population of bead, pellet, tablet or granule to be coated can be provided.

The population of pharmaceutical active substance can be made by layering the pharmaceutical active on sugar or cellulose spheres (herein

referred to as a core material), by extrusion spheronization or by mixing the pharmaceutical active substance with a selected excipient and compressing the mixture into tablets. An enteric coating is then provided to a portion of the population of the pharmaceutical active substance. The population
5 containing the basic substance can also be made by layering the basic substance on sugar or cellulose spheres (core material) or by extrusion spheronization or by mixing the basic substance with tablet excipients and compressing the mixture into tablets. An enteric coating is then provided to a portion of the population of the basic substance as desired.

10 The enteric coated populations of pharmaceutically active substance and populations of basic material should demonstrate a measure of acid resistance defined as the amount of active substance or basic material in tablets or pellets after being exposed to simulated gastric fluid, USP, or to 0.1M HCl(aq) relative to that of unexposed tablets or pellets, respectively. The
15 test is carried out in the following manner. The enteric coated beads, tablets or pellets are exposed to phosphate buffer pH 1.5 at a temperature of 37°C in a USP dissolution apparatus for 2 hours. The tablets should not disintegrate and release more than about 10% of the active or basic material. After two hours the enteric coating layered beads, pellets tablets or granules are
20 exposed to phosphate buffer (pH 7.2) and not less than about 70% of the active of basic material is released in one hour following such exposure.

The size of the sugar or cellulose spheres as a core material is not essential for the present invention but may vary between about 0.1 and about 4 mm. The spheres layered with pharmaceutical active substance or basic
25 material are produced either by powder or solution/suspension layering using for instance granulating or spray coating/layering equipment. Alternatively a population of pellets may be produced by extrusion/spheronization, balling or compression utilizing different process equipment as is understood by one of skill in the art. The size of the formulated core materials is approximately
30 between about 0.1 mm and 4 mm and typically, between about 0.1 mm and 2 mm. The manufactured core materials are then layered with the pharmaceutical active substance or the basic substance. Thus the size of the

prepared beads, pellets, tablets or granules may vary between about 0.1 to about 25mm and any size as desired therebetween. The tablets of the invention are made mixing the active substance or basic material with tableting excipients and compressed into a tablet to be included in the multi-
5 functional capsule according to the present invention.

The various populations of proton pump inhibitor and basic material is provided within a suitable capsule material as is understood by one of skill in the art. Suitable capsule materials may include for example but are not limited to gelatin, cellulose ethers, cellulose, biodegradable non-toxic
10 materials and combinations thereof. One of skill in the art would readily understand the process and manner of providing the oral composition of the invention within a capsule.

The preparation according to the invention is especially advantageous in reducing gastric acid secretion. Such a multi-functional capsule dosage
15 form may be administered one to several times a day depending on the formulation provided within a capsule. The typical daily dose of the pharmaceutical active substance may vary and will depend on various factors such as the individual requirements of the patients, the mode of administration and the disease. In general the daily dose will be in the range of 1-400 mg of
20 proton pump inhibitor or one of its single enantiomers or alkaline salts thereof. The preparation according to the present invention is also suitable for dispersion in an aqueous liquid with neutral or slightly acidic pH-value before being orally administered or fed through a naso-gastric tube.

Throughout the specification, it is understood that the term "a" or "an" may be interpreted to mean one or more.
25

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and
30 substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

ExamplesExample 1.*1. Preparation of pharmaceutical active loaded core material by extrusion spheronization*

- 5 This may be used without enteric coat as first population of pharmaceutical active substances

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
PPI (proton pump inhibitor)	40	30	30
Lactose	20	40	10
Starch	-	2	10
*Hydroxypropyl methyl cellulose	20	-	-
**Sodium lauryl sulfate	-	-	-
Microcrystalline cellulose	30	24	50
Eudragit™ NE 30 D	-	4	-
***Purified water	QS	QS	QS

* May be replaced or combined with Xanthan gum

** Sodium lauryl sulfate is optional

***Between 10% to 100% of the total weight of excipients used is sufficient

- 10 QS – quantity sufficient

2. Preparation of basic material loaded core material by extrusion spheronization

This may be used without enteric coat as a population of basic material

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
Basic (calcium carbonate)	40	30	30
Lactose	20	40	10
Starch 1500	-	2	10
Hydroxypropyl methyl cellulose	5	-	-
Sodium lauryl sulfate	1	2	1
Microcrystalline cellulose	45	26	49
*Purified water	QS	QS	QS

5 * Between 10% to 100% of the total weight of excipients used is sufficient

3. Preparation of the optional separation layer for populations of pharmaceutical active or basic material loaded spheres (core materials) to be enteric coated

	Formulation 1 (%) wgt
*Lustreclear™	9
Purified water	91

10 *Carrageenan preparation. Use 3% weight gain level

4. Preparation of the enteric coating layer for population of the pharmaceutical active or basic material loaded spheres (core materials) optionally provided with separating layer

	*Formulation (g)
Methacrylic acid copolymer	140
PEG 600	28
Talc	42
Purified water	500

5 *for coating 600g of active loaded spheres optionally covered with separating layer or 600g of spheres loaded with basic material

10 Sodium lauryl sulfate was dissolved in purified water and used as the granulation liquid. The PPI or basic material was dry mixed with excipients and then granulated with the aid of granulation liquid. The resultant wet mass was forced through an extruder equipped with screens with an aperture size of about 1.0 mm. The extrudate was spheronized on a friction plate in a spheronizing apparatus to form a core material which was then dried in a fluid bed dryer and classified if required.

15 Alternatively PPI loaded spheres were prepared by suspension layering in a fluid bed apparatus using a bottom spray technique as known to one of skill in the art. In this manner, the active was sprayed onto cellulose or sugar sphere from a water or alcohol/water suspension containing carrageenan or other suitable binder. The size of the spheres made was about 0.25 mm to about 2.0 mm.

20 The prepared core material was optionally covered with separating layer in a fluid bed apparatus with a Carrageenan/water solution. This is a population of pharmaceutical active substance or basic material.

25 To prepare further populations of beads or pellets containing pharmaceutical active or basic material, an enteric coating layer was applied to the population of beads or pellets containing pharmaceutical active or basic material, (which was previously optionally coated with a separating layer) using an aqueous dispersion of methacrylic acid copolymer plasticized with

polyethylene glycol via bottom spraying in a fluid bed. The beads or pellets were dried in a fluid bed apparatus.

Assembly of the capsule was done to contain the following;

- one population of pellets or beads containing pharmaceutical active substance designed to begin the release of the active substance in the stomach;
- one population of pellets or beads containing basic material designed to dissolve in the stomach and rapidly increases the pH of the stomach to not less than about 4.5 in less than about one hour;
- one population of enteric coated pellets or beads containing pharmaceutical active substance designed to release the active substance between the duodenum and just past the ileocecal junction; and
- one population of enteric coated pellets or beads containing the basic substance designed to release the basic material in and around the colon in order to maintain a colonic pH of not less than about 4.0.

Example 2

1. *This may be used without enteric coat as first population of pharmaceutical active substance.*

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
PPI (proton pump inhibitor)	15	15	15
Lactose	41	49	53
Starch 1500	5	5	-
*Hydroxypropyl methyl cellulose	12	-	-
**Sodium lauryl sulfate	-	-	-
Microcrystalline cellulose	16	20	20
Silicon dioxide	1	1	1
Magnesium stearate	1	1	1
***Methacrylic acid copolymer	-	-	10

Purified water	QS	-	QS
----------------	----	---	----

* May be replaced or combined with Xanthan gum

** Sodium lauryl sulfate is optional

*** Eudragit™ NE 30 D was used

5 *2. Preparation of basic material loaded core material by extrusion
spheronization*

This may be used without enteric coat as a population of basic material

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
Basic	70	71	71
Crospovidone	-	2	2
Silicon dioxide	1	1	1
Starch 1500	5	-	-
Sodium lauryl sulfate	9	10	10
Microcrystalline cellulose	14	15	15
Magnesium stearate	1	1	1
*Purified water	QS	-	QS

* Between 10% to 100% of the total weight of excipients used is sufficient

10 *3. Preparation of the optional separation layer for a population of
pharmaceutical active or basic material loaded tablets to be enteric coated*

	Formulation (%) wgt
*Lustreclear™	9
Purified water	91

*Carrageenan preparation. Use 3% weight gain level

4. Preparation of the enteric coating layer for a population of the pharmaceutical active or basic material loaded tablets optionally with separating layer

	*Formulation (g)
Methacrylic acid copolymer	140
PEG 600	28
Talc	42
Purified water	500

*for coating 2000g of active loaded tablets optionally covered with separating layer or 2000g of tablets loaded with basic material

Sodium lauryl sulfate was dissolved in purified water and used as the granulation liquid (use of sodium lauryl sulfate is optional). The PPI or basic material was dry mixed with excipients. The dry mix was granulated with aid of granulation liquid in a high shear mixer and the resultant wet granules were dried in a tray dryer oven or fluid bed. The dry granules were milled in a co-mill with screen size of about 1.0 mm. Lubricant was added to the milled granules and then blended in a V-blender. The blended granules were compressed into tablets. Dry granulation was used for formulation 2.

The tablets were optionally coated with separating layer in a side vented coating pan with a Carrageenan/water solution. This is a population of tablets containing pharmaceutical active substance or basic material.

To prepare further populations of tablets containing pharmaceutical active substance or basic material, the enteric coating layer was applied to a portion of the population of tablets containing pharmaceutical active substance or basic material, (which was previously optionally coated with separating layer) using an aqueous dispersion of methacrylic acid copolymer plasticized with polyethylene glycol. The tablets were dried in a coating pan.

Assembly of the multi-functional capsule was done to contain the following:

- one population of tablet containing pharmaceutical active substance designed to begin the release of the active substance in the stomach;
- one population of tablet containing basic material designed to dissolve in the stomach and rapidly increases the pH of the stomach to not less than about 4.5 in less than about one hour;
- one population of enteric coated tablet containing pharmaceutical active substance designed to release the pharmaceutical active substance between the duodenum and just past the ileocecal junction; and
- one population of enteric coated tablet containing the basic substance designed to release the basic material in and around the colon in order to maintain a colonic pH of not less than about 4.0.

Example 3.

1. Preparation of rapid release pharmaceutical active loaded tablets

- This may be used without enteric coat as first population of pharmaceutical active substances

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
PPI (proton pump inhibitor)	15	15	15
Lactose	48	49	53
Crospovidone	10	5	-
**Sodium lauryl sulfate	-	-	-
Microcrystalline cellulose	16	20	20
Silicon dioxide	1	1	1
Calcium stearate	1	1	1
***Methacrylic acid copolymer	-	-	-
Purified water	QS	-	QS

** Sodium lauryl sulfate is optional

***Between 10% to 100% of the total weight of excipients used is sufficient

QS – quantity sufficient

2. Preparation of sustained release pharmaceutical active loaded tablets

This may be used without enteric coat as second population of pharmaceutical active substances

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt	Formulation 4 (%) wgt
PPI (proton pump inhibitor)	15	15	15	15
Lactose	43	49	55.5	50.5
Starch 1500	-	-	-	-
*Hydroxypropyl methyl cellulose	15	10	7.5	-
**Sodium lauryl sulfate	-	-	-	-
Microcrystalline cellulose	16	15	20	20
Silicon dioxide	1	1	1	1
Calcium stearate	1	1	1	1
***Methacrylic acid copolymer	-	-	-	5
Purified water	QS	-	QS	15

* May be replaced or combined with Xanthan gum or hydroxy ethyl cellulose

5 ** Sodium lauryl sulfate is optional

*** EudragitTM NE 30 D was used

QS – quantity sufficient

3. Preparation of basic material loaded tablets

10 This may be used without enteric coat as a first population of basic material

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
Basic Substance(s) (calcium carbonate)	70	71	71
Crospovidone	-	2	2
Silicon Dioxide	1	1	1
Starch 1500	5	-	-
Sodium lauryl sulfate	9	10	10

Microcrystalline cellulose	14	15	15
Magnesium Stearate	1	1	1
*Purified water	QS	-	QS

* Between 70% to 100% of the total weight of excipients used is sufficient

4. Preparation of the optional separation layer for populations of pharmaceutical active or basic material loaded tablets to be enteric coated

	Formulation (%) wgt
*Lustreclear™	9
Purified water	91

5 *Carrageenan preparation. Use 3% weight gain level

5. Preparation of the enteric coating layer for population of the pharmaceutical active or basic material loaded tablets optionally provided with separating layer

	*Formulation (g)
Methacrylic acid copolymer	140
PEG 600	28
Talc	42
Purified water	500

10 *for coating 2000g of active loaded tablets optionally covered with separating layer or 2000g of tablets loaded with basic material

15 Sodium lauryl sulfate was dissolved in purified water and used as the granulation liquid (use of sodium lauryl sulfate is optional). The PPI or basic material was dry mixed with excipients and then granulated with the aid of granulation liquid in a high shear mixer. The resultant wet mass was dried in a tray dryer oven or fluid bed to form dry granules. The dry granules were milled in a co-mill equipped with screens with an aperture size of about 1.0

mm. Lubricant was added to the milled granules and blended in a V-blender. The blended granules were then compressed into tablets.

5 The tablets were optionally covered with separating layer in a side-vented coating pan with a Carrageenan/water solution. This is a population of pharmaceutical active substance or basic material.

If enteric coating is required, an enteric coating is applied to the populations of tablets containing pharmaceutical active or basic material. The enteric coating layer was applied to the population of tablets containing pharmaceutical active or basic material (which was previously optionally
10 coated with a separating layer) using an aqueous dispersion of methacrylic acid copolymer plasticized with polyethylene glycol. The tablets were dried in the coating pan.

Assembly of the capsule was done by encapsulating tablets from the multiple population to obtain a multifunctional oral dosage capsule form
15 containing the following;

- one population of tablets containing pharmaceutical active substance designed to begin the rapid release of the active substance in the stomach;
- one population of tablets containing basic material designed to dissolve in the stomach and rapidly increases the pH of the stomach to not
20 less than about 4.5 in less than about one hour; and
- one population of tablets (optionally enteric coated) containing pharmaceutical active substance designed to release the active substance in a sustained manner.

25 Example 4

This example is directed to a pulsed release capsule that comprises multiple populations of the pharmaceutical active in the form of a rapid release population, a delayed release population and a sustained release population together with multiple populations of a basic substance. Each population is
30 functionally distinct. The capsule provides the release of the pharmaceutical active in a pulsed release manner.

1. Preparation of rapid release pharmaceutical active loaded tablets

This may be used without enteric coat as first population of pharmaceutical active substances

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
PPI (proton pump inhibitor)	30	30	30
Lactose	28	28	53
Crospovidone	10	5	-
Sodium Starch glycolate			10
Sodium lauryl sulfate	-	5	-
Microcrystalline cellulose	30	30	2
Silicon dioxide	1	1	1
Magnesium stearate	1	1	1

5

2. Preparation of delayed release pharmaceutical active loaded tablets

The delayed release pharmaceutical active loaded tablets as second population of pharmaceutical active substances were prepared using rapid release pharmaceutical active loaded tablets prepared as above. The rapid release pharmaceutical active loaded tablets were first coated with an over coat of carrageenan, followed by an enteric coat. The formulae of the coats are shown below.

10

(I) Preparation of the over coat suspension for the delayed release pharmaceutical active loaded tablets

15

	Formulation (%) wgt
*Lustreclear™	9
Purified water	91

*Carrageenan preparation. Used 3% weight gain level

(II) Preparation of the enteric coat pseudolatex suspension for the delayed release pharmaceutical active loaded tablets

	*Formulation (g)
*Cellulose acetate phthalate (Aquacoat CPD™)	506
Diethyl phthalate	36.44
Purified water	712.4

*for coating 2000g of active loaded tablets optionally covered with separating layer or 2000g of tablets. The quantity of Aquacoat used contained 151.8 g of cellulose acetate phthalate.

5 3. Preparation of sustained release pharmaceutical active loaded tablets

This may be used without enteric coat as third population of pharmaceutical active substances

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt	Formulation 4 (%) wgt
PPI (proton pump inhibitor)	30	30	30	30
Lactose	30	30	30	30
Crospovidone	5	5	-	-
*Hydroxypropyl methyl cellulose	12	0-12	0-12	0-12
Pectin	0-10	10	0-10	0-10
Xanthan Gum	0-10	0-10	7	0-10
Carbomer	0-10	0-10	0-10	7
Microcrystalline cellulose	16	20	20	20
Silicon dioxide	1	1	1	1
Magnesium stearate	1	1	1	1

* May be replaced or combined with ethylcellulose and or hydroxyethyl cellulose

10 Prepared by direct compression

4. Preparation of basic material loaded tablets

This may be used with or without an enteric coat as a first population of basic material or granulated with ethylcellulose to impart a sustained release effect. An enteric coat impacts a delayed release effect.

	Formulation 1 (%) wgt	Formulation 2 (%) wgt	Formulation 3 (%) wgt
Basic	70	71	71
Crospovidone	-	2	2
Silicon dioxide	1	1	1
Starch 1500	5	-	-
Sodium lauryl sulfate	9	10	10
Microcrystalline cellulose	14	15	15
Magnesium stearate	1	1	1
*Purified water	QS	-	QS

May be prepared by direct compression or by wet granulation.

- 5 * Between 10% to 100% of the total weight of excipients used is sufficient.

10 Sodium lauryl sulfate was dissolved in purified water and used as the granulation liquid (use of sodium lauryl sulfate is optional). The PPI or basic material was dry mixed with excipients. The dry mix was granulated with aid of granulation liquid in a high shear mixer and the resultant wet granules were dried in a tray dryer oven or fluid bed. The dry granules were milled in a co-mill with screen size of about 1.0 mm. Lubricant was added to the milled granules and then blended in a V-blender. The blended granules were compressed into tablets.

15 The tablets were optionally coated with separating layer in a side vented coating pan with a Carrageenan/water solution. This is a population of tablets containing pharmaceutical active substance or basic material.

20 If enteric coating is required, an enteric coating is applied to the populations of tablets containing pharmaceutical active or basic material. The enteric coating layer was applied to the population of tablets containing pharmaceutical active or basic material (which was previously optionally coated with a separating layer) using an aqueous dispersion of methacrylic

acid copolymer plasticized with polyethylene glycol. The tablets were dried in the coating pan.

Assembly of the capsule was done by encapsulating tablets from the multiple population to obtain a multifunctional oral dosage capsule form

5 containing the following;

- one population of tablets containing pharmaceutical active substance designed to begin the rapid release of the active substance in the stomach;

- one population of tablets (optionally enteric coated) containing pharmaceutical active substance designed to release the active substance in a sustained manner;

10

- one population of tablets containing pharmaceutical active substance designed to release the active substance in a delayed manner; and

- one population of tablets containing basic material designed to release the basic material in a rapid, sustained or delayed manner.

15 Although certain embodiments have been described herein in detail it is understood by those of skill in the art that using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein can be made. Such equivalents are intended to be encompassed by the scope of the claims appended hereto.

WHAT IS CLAIMED IS:

1. An oral pharmaceutical composition comprising multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the
5 composition comprising:
 - (i) a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate;
 - (ii) a population of a basic substance; and
 - (iii) a second population of a pharmaceutical active comprising a
10 pharmaceutical active substance releasable at a second rate.
2. The composition of claim 1, wherein the first rate of release is faster than the second rate of release.
- 15 3. The composition of claim 1 or 2, wherein the second rate of release is release in at least one of a delayed and sustained manner.
4. The composition of any one of claims 1 to 3, further comprising a third population of a pharmaceutical active comprising a pharmaceutical active
20 substance being releasable at a third rate.
5. The composition of claim 4, wherein the first rate of release is a release in a rapid manner, the second rate of release is release in at least one of a delayed and sustained manner, and the third rate of release is release in at
25 least one of a delayed and sustained manner.
6. The composition of any one of claims 1 to 5, wherein the oral pharmaceutical composition is a pulsed release capsule.
- 30 7. The composition of any one of claims 1 to 6, wherein at least one of (i), (ii) and (iii) further comprise at least one excipient.

8. The composition of claim 7, wherein said at least one excipient is selected from the group consisting of binders, surfactants, fillers, lubricants, disintegrating agents, sustained release agents, and combinations thereof.
- 5 9. The composition of claim 7 or 8, wherein said at least one excipient of (i) to (iii) is present in an amount of about 0.5% to about 95% by weight of said beads, pellets, tablets or granules of said population.
- 10 10. The composition of any one of claims 7 to 9, wherein said at least one excipient of (iii) is a sustained release agent.
- 15 11. The composition of any one of claims 7 to 10, wherein said at least one excipient of (i) serves to release the pharmaceutical active substance of the first population faster than the pharmaceutical active substance of the second population.
12. The composition of claim 11, wherein said at least one excipient of (i) is a disintegrating agent.
- 20 13. The composition of any one of claims 1 to 12, wherein the pharmaceutical active of (iii) further comprises an enteric coating.
- 25 14. The composition of claim 13, wherein a separating layer is provided to separate the pharmaceutical active of (iii) from contact with the enteric coating.
- 30 15. The composition of any one of claims 1 to 14 further comprising (iv) a population of a basic substance, wherein the basic substance is released slower than the basic substance of (ii).
16. The composition of claim 15, wherein the basic substance of (iv) further comprises an enteric coating.

17. The composition of claim 16, wherein a separating layer is provided to separate the basic substance of (iv) from contact with the enteric coating.
- 5 18. The composition of any one of claims 1 to 17, wherein the pharmaceutical active substance of the first population is the same as the pharmaceutical active substance of the second population.
- 10 19. The composition of any one of claims 1 to 18, wherein at least one of the pharmaceutical active substances of (i) and (iii) comprises an acid labile drug.
- 15 20. The composition of claim 19, wherein said at least one of the pharmaceutical active substances of (i) and (iii) comprises at least one of a proton pump inhibitor, a prodrug of a proton pump inhibitor, a single enantiomer of a proton pump inhibitor, a single enantiomer of a prodrug of a proton pump inhibitor, and combinations thereof.
- 20 21. The composition of any one of claims 1 to 20, wherein said basic substance is selected from the group consisting of sodium, potassium, calcium, magnesium and aluminum salts of phosphoric acid, carbonic acid, and citric acid; aluminum hydroxide; sodium bicarbonate; aluminum, calcium and magnesium hydroxides; magnesium oxide; trihydroxymethylaminomethane; basic amino acids or their salts; and mixtures thereof.
- 25 22. The composition of any one of claims 1 to 21, wherein (i) provides delivery of the pharmaceutical active to the stomach upon oral administration.
- 30 23. The composition of any one of claims 1 to 22, wherein (iii) provides delivery of the pharmaceutical active between the duodenum and just past the ileocecal junction.

24. The composition of claim 1, wherein (ii) is rapidly released in the stomach and increases the stomach pH to more than about 4 and less than about 7 in less than about 1 hour, wherein the pharmaceutical active of (i) is rapidly or gradually released in the stomach.

25. The composition of claim 24, wherein (ii) is rapidly released in the stomach and increases the stomach pH to more than about 4 and less than about 7 in less than about 1 hour, wherein the pharmaceutical active of (i) is rapidly or gradually released in the stomach.

26. The composition of claim 15, wherein (ii) is rapidly released in the stomach and increases the stomach pH to more than about 4 and less than about 7 in less than about 1 hour, wherein the pharmaceutical active of (i) is rapidly or gradually released in the stomach, (iii) provides delivery of the pharmaceutical active between the duodenum and just past the ileocecal junction, and (iv) releases said basic substance just past the ileocecal junction.

27. The composition of claim 8, wherein said sustained release agents are selected from the group consisting of pectin, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carragenan, xanthan gum, carbomer and mixtures thereof.

28. The composition of claim 8, wherein said disintegrating agents are selected from the group consisting of homopolymer cross-linked N-vinyl-2-pyrrolidone, sodium starch glycolate, cross-linked sodium carboxymethylcellulose and mixtures thereof.

29. A method for treating conditions caused by inappropriate gastric acid secretion, said method comprising administering the composition of any one of claims 1 to 28 to a subject in need of such treatment.

5 30. The method of claim 29, wherein said inappropriate gastric acid secretion is night time acid secretion and said administration is done at night time.

10 31. An oral pharmaceutical composition comprising multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising:

- (i) a population of a pharmaceutical active;
- (ii) a population of a basic substance;
- (iii) a population of enteric coated pharmaceutical active; and
- 15 (iv) a population of enteric coated basic substance.

20 32. The composition of claim 31, wherein a separating layer is provided to said population of enteric coated pharmaceutical active, said separating layer being provided to separate said pharmaceutical active from contact with said enteric coating.

25 33. The composition of claim 31 or 32, wherein a separating layer is provided to said population of enteric coated basic substance, said separating layer being provided to separate said basic substance from contact with said enteric coating.

34. The composition of any one of claims 31 to 33, wherein at least one excipient is provided to at least one of (i) to (iv).

30 35. The composition of claim 34, wherein said at least one excipient is selected from the group consisting of binders, surfactants, fillers, lubricants, disintegrating agents, sustained release agents, and combinations thereof.

36. The composition of claim 34 or 35, wherein said at least one excipient is present in an amount of about 0.5% to about 95% by weight of said beads, pellets, tablets or granules of said population.

5

37. The composition of any one of claims 31 to 36, wherein at least one over-coating layer is provided to at least one of said population of (i) to (iv).

10

38. The composition of any one of claims 31 to 38, wherein said pharmaceutical active comprises an acid labile drug.

15

39. The composition of claim 38, wherein said pharmaceutical active comprises a proton pump inhibitor, a prodrug of a proton pump inhibitor, a single enantiomer of a proton pump inhibitor, a single enantiomer of a prodrug of a proton pump inhibitor, and combinations thereof.

20

40. The composition of any one of claims 31 to 39, wherein said basic substance is selected from the group consisting of sodium, potassium, calcium, magnesium and aluminum salts of phosphoric acid, carbonic acid, and citric acid; aluminum hydroxide; sodium bicarbonate; aluminum, calcium and magnesium hydroxides; magnesium oxide; trihydroxymethylaminomethane; basic amino acids or their salts; and mixtures thereof.

25

41. The composition of claim 40, wherein said basic substance is calcium carbonate.

30

42. The composition of any one of claims 31 to 41, wherein said population of any one of (i) to (iv) is made by extrusion pherionization or compression into tablets.

43. The composition of any one of claims 31 to 42, wherein (i) begins delivery of said active in the stomach upon oral administration.

44. The composition of any one of claims 31 to 43, wherein (i) provides delivery of said active to the stomach, (iii) provides delivery of said active between the duodenum and just past the ileocecal junction and (iv) provides delivery of said active to the ascending, transverse and descending colon.

45. The composition of any one of claims 31 to 43, wherein (ii) is rapidly released in the stomach and increases the stomach pH to more than about 4 and less than about 7 in less than 1 hour, wherein (i) is rapidly or gradually released in the stomach, (iii) provides rapid or gradual release of active between the duodenum and just past the ileocecal junction and (iv) releases said basic substance just past the ileocecal junction.

46. A method for treating conditions caused by inappropriate gastric acid secretion, said method comprising administering the composition of any one of claims 31 to 45 to a subject in need of such treatment.

47. The method of claim 46, wherein said inappropriate gastric acid secretion is night time acid secretion and said administration is done at night time.

48. A method for making the composition of claim 31, said method comprising;

- (a) providing a pharmaceutical active or basic substance to a core material to provide a population of (i) and (iii);
- (b) providing one or more enteric coating layers to a portion of (a); and
- (c) providing (a) and (b) within a capsule.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000825

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/48 A61K9/28 A61K9/20 A61K9/50 A61K31/44
A61P1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 1 017 370 A (NYCOMED DANMARK A S) 12 July 2000 (2000-07-12) claims 1-48 paragraphs '0085! - '0132! examples 7-14	1-48
A	WO 03/009846 A (UNIV MISSOURI) 6 February 2003 (2003-02-06) claims 1-35 examples 1-10 page 23, line 10 - page 29, line 22	1-48
A	US 2002/045646 A1 (PHILLIPS JEFFREY O) 18 April 2002 (2002-04-18) claims 1-16 paragraphs '0077! - '0137! ----- -/-	1-48



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 October 2004

Date of mailing of the international search report

22/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schifferer, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA2004/000825

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 6 489 346 B1 (PHILLIPS JEFFREY OWEN) 3 December 2002 (2002-12-03) claims 1-23 examples 6,7,9 column 12, line 12 - column 18, line 27 -----</p>	1-48

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/000825

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 29, 30, 46-48 (in part)
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 29-30, 46-48 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA2004/000825

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1017370	A	12-07-2000	AT 252892 T	15-11-2003
			AU 9062998 A	29-03-1999
			CA 2301883 A1	18-03-1999
			DE 69819351 D1	04-12-2003
			EA 2806 B1	31-10-2002
			EP 1017370 A1	12-07-2000
			JP 2001515854 T	25-09-2001
			NO 20001290 A	28-04-2000
			US 6599529 B1	29-07-2003
			CN 1277550 T	20-12-2000
			WO 9912524 A1	18-03-1999
WO 03009846	A	06-02-2003	US 2002045646 A1	18-04-2002
			BR 0210971 A	24-08-2004
			CA 2453117 A1	06-02-2003
			EP 1414452 A1	06-05-2004
			JP 2004521955 T	22-07-2004
			WO 03009846 A1	06-02-2003
			US 2003191159 A1	09-10-2003
			US 2004048896 A1	11-03-2004
			US 2004171646 A1	02-09-2004
US 2002045646	A1	18-04-2002	US 6489346 B1	03-12-2002
			US 5840737 A	24-11-1998
			BR 0210971 A	24-08-2004
			CA 2453117 A1	06-02-2003
			EP 1414452 A1	06-05-2004
			JP 2004521955 T	22-07-2004
			WO 03009846 A1	06-02-2003
			US 2003191159 A1	09-10-2003
			US 2004048896 A1	11-03-2004
			US 2004171646 A1	02-09-2004
			AU 3276701 A	24-07-2001
			BR 0107565 A	11-02-2003
			CA 2396159 A1	19-07-2001
			EP 1246622 A1	09-10-2002
			EP 1430895 A1	23-06-2004
			JP 2003519656 T	24-06-2003
			NO 20023313 A	30-08-2002
			PL 357144 A1	12-07-2004
			WO 0151050 A1	19-07-2001
			US 2003118669 A1	26-06-2003
			US 2003144306 A1	31-07-2003
			US 2003215527 A1	20-11-2003
			US 2004058018 A1	25-03-2004
			ZA 200205512 A	10-02-2004
			AU 1907100 A	22-05-2000
			WO 0026185 A2	11-05-2000
US 6489346	B1	03-12-2002	US 5840737 A	24-11-1998
			AU 3276701 A	24-07-2001
			BR 0107565 A	11-02-2003
			CA 2396159 A1	19-07-2001
			EP 1246622 A1	09-10-2002
			EP 1430895 A1	23-06-2004
			JP 2003519656 T	24-06-2003
			NO 20023313 A	30-08-2002
			PL 357144 A1	12-07-2004

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA2004/000825

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6489346	B1	WO 0151050 A1	19-07-2001
		US 2003191159 A1	09-10-2003
		US 2003118669 A1	26-06-2003
		US 2003144306 A1	31-07-2003
		US 2003215527 A1	20-11-2003
		US 2004048896 A1	11-03-2004
		US 2004058018 A1	25-03-2004
		US 2004171646 A1	02-09-2004
		US 2002045646 A1	18-04-2002
		ZA 200205512 A	10-02-2004
		AU 1907100 A	22-05-2000
		WO 0026185 A2	11-05-2000

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☒ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)